CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival

Neurology

Volumn 83, Issue 21, 2014, Pages 1945-1953

  Skillbäck, Tobias ^a   Farahmand, Bahman ^b,d   Bartlett, Jonathan W ^e   Rosén, Christoffer ^a   Mattsson, Niklas ^a,f   Nägga, Katarina ^g   Kilander, Lena ^h   Religa, Dorota ^b,d   Wimo, Anders ^c   Winblad, Bengt ^b   Rosengren, Lars ^a   Schott, Jonathan M ⁱ   Blennow, Kaj ^a   Eriksdotter, Maria ^b,d   Zetterberg, Henrik ^a,i  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Care Sciences and Society ^*  (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g LUND UNIVERSITY   (Sweden)

^h UPPSALA UNIVERSITY   (Sweden)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; TAU PROTEIN; NEUROFILAMENT PROTEIN; NEUROFILAMENT PROTEIN L;

ADULT; AGE; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEMENTIA; DEMENTIA NOT OTHERWISE SPECIFIED; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE SEVERITY; EARLY ONSET ALZHEIMER DISEASE; FEMALE; FRONTOTEMPORAL DEMENTIA; GRAY MATTER; HUMAN; LIGHT; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MIXED ALZHEIMER DISEASE; MULTIINFARCT DEMENTIA; NEUROFILAMENT; NEUROFILAMENT LIGHT; PARKINSON DISEASE WITH DEMENTIA; PREDICTION; PRIORITY JOURNAL; SURVIVAL; SURVIVAL TIME; MIDDLE AGED; MORTALITY; NEURODEGENERATIVE DISEASES; PREDICTIVE VALUE; REGISTER; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TRENDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURODEGENERATIVE DISEASES; NEUROFILAMENT PROTEINS; PREDICTIVE VALUE OF TESTS; REGISTRIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 84922481519     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001015     Document Type: Article

References (37)

1. Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 2005;233:183-198.
2. Schlaepfer WW, Lynch RG. Immunofluorescence studies of neurofilaments in the rat and human peripheral and central nervous system. J Cell Biol 1977;74:241-250.
3. Zetterberg H, Hietala MA, Jonsson M, et al. Neurochemical aftermath of amateur boxing. Arch Neurol 2006;63: 1277-1280.
4. Lycke JN, Karlsson JE, Andersen O, Rosengren LE. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neuro-surg Psychiatry 1998;64:402-404.
5. Zanier ER, Refai D, Zipfel GJ, et al. Neurofilament light chain levels in ventricular cerebrospinal fluid after acute aneurysmal subarachnoid haemorrhage. J Neurol Neuro-surg Psychiatry 2011;82:157-159.
6. Sjogren M, Blomberg M, Jonsson M, et al. Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J Neurosci Res 2001;66:510-516.
7. Jonsson M, Zetterberg H, van Straaten E, et al. Cerebrospinal fluid biomarkers of white matter lesions: cross-sectional results from the LADIS Study. Eur J Neurol 2010;17:377-382.
8. Landqvist Waldo M, Frizell Santillo A, Passant U, et al. Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia. BMC Neurol 2013;13:54.
9. Madeddu R, Farace C, Tolu P, et al. Cytoskeletal proteins in the cerebrospinal fluid as biomarker of multiple sclerosis. Neurol Sci 2013;34:181-186.
10. Jeppsson A, Zetterberg H, Blennow K, Wikkelso C. Idiopathic normal-pressure hydrocephalus: pathophysiology and diagnosis by CSF biomarkers. Neurology 2013;80: 1385-1392.
11. Tortelli R, Ruggieri M, Cortese R, et al. Elevated cerebro-spinal fluid neurofilament light levels in patients with amy-otrophic lateral sclerosis: a possible marker of disease severity and progression. Eur J Neurol 2012;19:1561-1567.
12. Hagberg L, Fuchs D, Rosengren L, Gisslen M. Intrathecal immune activation is associated with cerebrospinal fluid markers of neuronal destruction in AIDS patients. J Neuroimmunol 2000;102:51-55.
13. Mattsson N, Bremell D, Anckarsater R, et al. Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism. BMC Neurol 2010;10:51.
14. SveDem. About SveDem: Swedish Dementia Registry. Available at: http://www.ucr.uu.se/svedem/index.php/about-svedem. Accessed September 18, 2013.
15. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. Geneva: World Health Organization; 1993.
16. The Lund and Manchester Groups. Clinical and neuro-pathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry 1994;57:416-418.
17. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-1872.
18. Martinez-Martin P, Falup-Pecurariu C, Rodriguez-Blazquez C, et al. Dementia associated with Parkinson's disease: applying the Movement Disorder Society Task Force criteria. Parkinsonism Relat Disord 2011;17:621-624.
19. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-260.
20. Sorbi S, Hort J, Erkinjuntti T, et al. EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol 2012;19:1159-1179.
21. Hall S, Ohrfelt A, Constantinescu R, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012;69:1445-1452.
22. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF bio-markers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228-234.
23. Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 2014;13:614-629.
24. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 1996;67: 2013-2018.
25. Scherling CS, Hall T, Berisha F, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in fron-totemporal degeneration. Ann Neurol 2014;75:116-126.
26. Pijnenburg YA, Janssen JC, Schoonenboom NS, et al. CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer's disease and controls. Dement Geriatr Cogn Disord 2007;23:225-230.
27. Sellner J, Patel A, Dassan P, Brown MM, Petzold A. Hyperacute detection of neurofilament heavy chain in serum following stroke: a transient sign. Neurochem Res 2011;36:2287-2291.
28. Romme Christensen J, Bornsen L, Khademi M, et al. CSF inflammation and axonal damage are increased and corre late in progressive multiple sclerosis. Mult Scler 2013;19: 877-884.
29. Nylen K, Csajbok LZ, Ost M, et al. CSF-neurofilament correlates with outcome after aneurysmal subarachnoid hemorrhage. Neurosci Lett 2006;404:132-136.
30. Petzold A, Keir G, Warren J, Fox N, Rossor MN. A systematic review and meta-analysis of CSF neurofilament protein levels as biomarkers in dementia. Neurodegener Dis 2007;4:185-194.
31. Rosengren LE, Karlsson JE, Sjogren M, Blennow K, Wallin A. Neurofilament protein levels in CSF are increased in dementia. Neurology 1999;52:1090-1093.
32. de Jong D, Jansen RW, Pijnenburg YA, et al. CSF neurofilament proteins in the differential diagnosis of dementia. J Neurol Neurosurg Psychiatry 2007;78:936-938.
33. Mahoney CJ, Downey LE, Ridgway GR, et al. Longitudinal neuroimaging and neuropsychological profiles of frontotemporal dementia with C9ORF72 expansions. Alzheimers Res Ther 2012;4:41.
34. Sjogren M, Wallin A. Pathophysiological aspects of frontotemporal dementia: emphasis on cytoskeleton proteins and autoimmunity. Mech Ageing Dev 2001;122: 1923-1935.
35. Kawamura J, Terayama Y, Takashima S, et al. Leuko-araiosis and cerebral perfusion in normal aging. Exp Aging Res 1993; 19:225-240.
36. Pantoni L, Garcia JH, Gutierrez JA. Cerebral white matter is highly vulnerable to ischemia. Stroke 1996;27:1641-1646.
37. Mathuranath PS, Nestor PJ, Berrios GE, Rakowicz W, Hodges JR. A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia. Neurology 2000;55:1613-1620.